Zelira Therapeutics (ZLD) AI Stock Analysis

• Market Cap: AU$5.23M
• Dividend Yield: N/A
• Average Volume (3M): 5.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -85.34%
• EPS Growth: 86.74%
• Country: AU
• Employees: 8
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 11,897,155
• 10 Day Avg. Volume: 8,084
• 30 Day Avg. Volume: 5,294
• PEG Ratio: 0.52
• Price to Book (P/B): 1.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: AU$0.50 ▲(13.64%Upside)

Zelira Therapeutics has a low overall stock score primarily due to its poor financial performance indicated by persistent losses, negative equity, and cash flow inefficiencies. Technical analysis suggests continued bearish momentum, and the valuation is unattractive due to the lack of profitability.

Zelira Therapeutics Business Overview & Revenue Model

Company Description

Zelira Therapeutics (ZLD) is a global biopharmaceutical company focused on researching, developing, and commercializing clinically validated cannabinoid-based medicines. Zelira operates in the healthcare and pharmaceutical sectors, dedicated to advancing treatments for a variety of medical conditions. The company is particularly renowned for its proprietary formulations targeting insomnia, autism, and chronic non-cancer pain.

How the Company Makes Money

Zelira Therapeutics generates revenue primarily through the commercialization of its cannabinoid-based medicines. This includes direct product sales, licensing agreements, and strategic partnerships. The company collaborates with international healthcare distributors and pharmaceutical companies to market and distribute its products globally. Additionally, Zelira engages in research and development collaborations, which may include milestone payments and royalties. These partnerships and licensing agreements significantly contribute to its revenue streams. The company also explores opportunities in over-the-counter (OTC) markets to broaden its consumer base and revenue potential.

Zelira Therapeutics Financial Statement Overview

Summary

Zelira Therapeutics faces significant financial challenges, including declining revenue, negative profit margins, and negative equity. Cash flow issues further compound these problems, with consistent cash outflows indicating poor financial health and high leverage.

Income Statement

Zelira Therapeutics has demonstrated declining revenue over the years, with the latest revenue significantly lower than previous years. Gross and net profit margins are negative, indicating unprofitable operations. EBIT and EBITDA margins are also negative, showing operational inefficiency and high costs relative to revenue.

Balance Sheet

The balance sheet reveals a concerning financial structure, with a negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is unfavorable due to negative equity, and the equity ratio is negative, highlighting financial instability.

Cash Flow

Cash flow analysis shows negative free cash flow and operating cash flow, indicating cash outflows in operations. Despite some financing inflows, the free cash flow to net income ratio suggests poor cash conversion. The operating cash flow to net income ratio is also negative, reflecting inefficiencies.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	40.88K	94.95K	301.12K	1.54M	663.32K	0.00
Gross Profit	-285.19K	10.28K	-3.22M	-5.72M	-39.16K	-275.05K
EBITDA	-3.98M	-36.44M	-6.87M	-12.83M	-9.18M	-7.71M
Net Income	-4.84M	-36.57M	-5.57M	-11.95M	-8.55M	-7.02M
Balance Sheet
Total Assets	2.39M	5.18M	33.89M	37.70M	39.37M	35.79M
Cash, Cash Equivalents and Short-Term Investments	38.19K	586.16K	146.21K	2.75M	4.97M	1.70M
Total Debt	6.30M	5.95M	437.90K	500.91K	551.08K	632.32K
Total Liabilities	10.36M	9.36M	2.18M	2.01M	1.54M	1.24M
Stockholders Equity	-8.40M	-4.51M	31.80M	35.20M	37.83M	34.55M
Cash Flow
Free Cash Flow	-5.29M	-4.39M	-7.25M	-9.43M	-8.62M	-6.95M
Operating Cash Flow	-5.29M	-4.39M	-7.25M	-9.43M	-8.62M	-6.94M
Investing Cash Flow	919.74K	919.74K	2.83M	-207.78K	1.38M	1.11M
Financing Cash Flow	4.36M	3.92M	1.77M	7.10M	10.53M	4.50M

Zelira Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.43, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZLD.

Zelira Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXC	57 Neutral	AU$6.84M	60.67	2.14%	―	―	―
NSB	54 Neutral	AU$43.23M	17.07	26.99%	―	―	51.85%
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
1AD	46 Neutral	AU$2.68M	―	-392.18%	―	―	34.26%
AVE	46 Neutral	AU$11.11M	―	-64.72%	―	139.19%	33.33%
ZLD	40 Underperform	AU$5.23M	―	-263.02%	―	-85.34%	86.74%

Zelira Therapeutics Corporate Events

Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study

Zelira Therapeutics announced the publication of a clinical study demonstrating the efficacy and safety of its proprietary cannabinoid-based therapy, ZLT-L-007, in treating diabetic neuropathy. The study showed that ZLT-L-007 significantly outperformed Lyrica® (Pregabalin) in reducing pain and improving quality of life for patients, marking a potential shift in the standard-of-care treatment for diabetic neuropathy. The study, conducted under rigorous clinical standards, reported no serious adverse events, suggesting a promising future for ZLT-L-007 in the market.

Zelira Therapeutics Strengthens Financial Position and Advances Product Development

Zelira Therapeutics has enhanced its financial flexibility by receiving a $1.15 million R&D Tax Incentive refund and establishing a $1 million At-the-Market funding facility. These financial moves support its ongoing development programs, including preparations for the FDA clinical trial of HOPE® 1. The company also completed the full conversion of US$3.25 million convertible notes into equity, strengthening its capital structure. The development of capsule formulations for HOPE® and Zenivol® using Zyraydi™ technology is on track for completion in mid to late 2025, aligning with Zelira’s strategy to enhance product consistency and market readiness.

Zelira Therapeutics Converts $3.25M Notes to Equity, Advances Autism Treatment Trials

Zelira Therapeutics has announced the full conversion of $USD3.25 million in Convertible Notes into equity within its HOPE® 1 SPV, which supports the clinical and regulatory development of treatments for Autism Spectrum Disorder. This conversion aligns investor interests, eliminates debt obligations, and strengthens the SPV’s capital structure, positioning it well for future institutional capital raises. The company has made significant progress in its clinical trial program, having completed a Pre-IND meeting with the U.S. FDA, which confirmed the appropriateness of targeting Phelan-McDermid Syndrome, a rare subset of Autism, for study. Zelira is now focused on submitting an IND to the FDA, initiating Phase 1 clinical trials, and filing for Orphan Drug Designation to leverage regulatory incentives.